Cobicistat: A case of mislabelled drug‐drug interaction risk?

This editorial discusses cobicistat, licensed for its potential to enhance the effects of antiretrovirals by acting as CYP3A inhibitor. The editorial highlights that although it is structurally similar to ritonavir, the SPC listing of interactions based on this is inappropriate

British Journal of Clinical Pharmacology